BBI Solutions highlights its global capabilities in 2021 customer campaign

Crumlin-headquartered manufacturer and leading supplier of immunodiagnostic reagents, BBI Solutions has today launched a 2021 customer campaign, showcasing its global capabilities in serving the science of diagnostics.

The company is using multiple marketing platforms, including a new website and video, to underpin the campaign.

With contributions from world-class scientists and technical leaders at BBI Solutions’ seven manufacturing sites across four continents, demonstrating integration of their global expertise and the real-world impacts of their products and services to the diagnostics industry and to its customers and patients, the video showcases the breadth and depth of BBI’s portfolio while highlighting a commitment to immunodiagnostic platforms and lateral point-of-care tests.

BBI Solutions’ production and supply of critical immunoassay components such as antibodies, antigens, enzymes and particles feature prominently in the video, as well as other key services such as the development of products from concept to point of care and their innovative mobile diagnostic platform, Novarum™.

The global capabilities also feature prominently on the company’s recently enhanced website, which has been designed with the customer at its heart to create a seamless and enjoyable browsing experience with information on BBI’s varied services easily accessible.

Dr Mario Gualano, Chief Executive of BBI Group, said: “I feel privileged to lead BBI Solutions in our continued growth during the last year in unprecedented times, which presented unique challenges and opportunities. We have made significant investments in our production capabilities and increased our immunodiagnostics offering by creating BBI Freiburg. We could not have achieved this without the commitment and collaboration of our colleagues across the globe.”

The launch follows a successful year for BBI which included the acquisition of Freiburg-based DIARECT, a leading supplier of autoimmune antigen products; membership of the UK-Rapid Test Consortium to develop and rollout coronavirus tests; and the development of two new recombinant SARS-Cov-2 antigens, designed as critical raw materials for next generation serological assays.

The company has multiple sites across the globe including Crumlin, Edinburgh, Sittingbourne, Porton Down, Freiburg, Cape Town, Portland and Shanghai.

For further information about BBI Solutions and their global capabilities, visit

To see BBI Solutions’ new video click here.